Analysts cut Schott Pharma, expect 2026 to be transition year

SCHOTT Pharma AG & Co KgaA

08/12/2025 12:41

** Barclays and DB cut German medical equipment supplier Schott Pharma 1SXP.DE to "equal-weight" from "overweight" and to "hold" from "buy", respectively, expecting 2026 to be a transition year after the group cut its mid-term outlook

** "The big disappointment was the new FY26 guidance," Deutsche Bank says, while also lowering its PT by almost 35% to 19 euros

**  Barclays notes that 2026 will be a transition year as Schott navigates a change in the core management team - with a new CEO starting in May - and challenging market conditions, especially on the glass syringe market

** It also cuts its PT by more than 46% to 15 euros

** The stock falls 5.7%, extending losses of nearly 7% in the previous session

** Out of 13 analysts that cover Schott Pharma, 11 rate the stock "strong buy" or "buy," one "hold" and one "sell" - LSEG data

 (Reporting by Amir Orusov)

 ((Amir.orusov@thomsonreuters.com))